Publications

Titlesort descending Year
Amoxicillin/clavulanate in combination with rifampicin/clarithromycin is bactericidal against Mycobacterium ulcerans 2024
Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains. 2013
Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial) 2022
Evaluation of critical parameters in the hollow-fibre system for tuberculosis: A case study of moxifloxacin 2024
Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium 2023
In vitro synergy screens of FDA-approved drugs reveal novel zidovudine- and azithromycin-based combinations with last-line antibiotics against Klebsiella pneumoniae 2023
Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency 2020
Repurposing Avermectins and Milbemycins against Mycobacteroides abscessus and Other Nontuberculous Mycobacteria 2021
Repurposing clinically approved cephalosporins for tuberculosis therapy. 2016
Repurposing β-Lactams for the Treatment of Mycobacterium kansasii Infections: An In Vitro Study 2023
Sanfetrinem, repurposing an oral beta-lactam with intracellular activity for the treatment of tuberculosis 2019
Susceptibility testing of the live attenuated tuberculosis vaccine BCG and the vaccine candidate MTBVAC to currently WHO-recommended anti-tuberculosis drugs by the European committee on antimicrobial susceptibility testing (EUCAST) method 2024
Targeting Tuberculosis: Existing drugs can - and should - be repurposed to fight neglected diseases. 2017
Targeting Tuberculosis: Existing drugs can – and should – be repurposed to fight neglected diseases. 2017
The FICI paradigm: correcting flaws in antimicrobial in vitro synergy screens at their inception. 2019
The novel drug candidate VOMG kills Mycobacterium abscessus and other pathogens by inhibiting cell division 2024
The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme 2022
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening 2018
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening 2019